Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy

被引:64
|
作者
McManus, Hamish [1 ]
O'Connor, Catherine C. [2 ,3 ,4 ]
Boyd, Mark [1 ]
Broom, Jennifer [5 ]
Russell, Darren [6 ]
Watson, Kerrie [7 ]
Roth, Norman [8 ]
Read, Phillip J. [9 ]
Petoumenos, Kathy [1 ]
Law, Matthew G. [1 ]
机构
[1] UNSW, Kirby Inst, Sydney, NSW, Australia
[2] Royal Prince Alfred Hosp, RPA Sexual Hlth, Sydney, NSW, Australia
[3] UNSW, S Western Clin Sch, Sydney, NSW, Australia
[4] Univ Sydney, Cent Clin Sch, Sydney, NSW 2006, Australia
[5] Nambour Gen Hosp, Dept Infect Dis, Nambour, Qld, Australia
[6] Cairns Sexual Hlth Serv, Cairns, Qld, Australia
[7] Alfred Hosp, Melbourne, Vic, Australia
[8] Prahran Market Clin, Prahran, Vic, Australia
[9] Sydney Sexual Hlth Ctr, Sydney, NSW, Australia
来源
PLOS ONE | 2012年 / 7卷 / 11期
基金
美国国家卫生研究院;
关键词
LIFE EXPECTANCY; CONTROLLED-TRIAL; CELL COUNTS; MORTALITY; COHORT; INFECTION; DIAGNOSIS; PEOPLE; IMPACT;
D O I
10.1371/journal.pone.0048839
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Life expectancy has increased for newly diagnosed HIV patients since the inception of combination antiretroviral treatment (cART), but there remains a need to better understand the characteristics of long-term survival in HIV-positive patients. We examined long-term survival in HIV-positive patients receiving cART in the Australian HIV Observational Database (AHOD), to describe changes in mortality compared to the general population and to develop longer-term survival models. Methods: Data were examined from 2,675 HIV-positive participants in AHOD who started cART. Standardised mortality ratios (SMR) were calculated by age, sex and calendar year across prognostic characteristics using Australian Bureau of Statistics national data as reference. SMRs were examined by years of duration of cART by CD4 and similarly by viral load. Survival was analysed using Cox-proportional hazards and parametric survival models. Results: The overall SMR for all-cause mortality was 3.5 (95% CI: 3.0-4.0). SMRs by CD4 count were 8.6 (95% CI: 7.2-10.2) for CD4<350 cells/mu l; 2.1 (95% CI: 1.5-2.9) for CD4 = 350-499 cells/mu l; and 1.5 (95% CI: 1.1-2.0) for CD4 >= 500 cells/mu l. SMRs for patients with CD4 counts<350 cells/mu l were much higher than for patients with higher CD4 counts across all durations of cART. SMRs for patients with viral loads greater than 400 copies/ml were much higher across all durations of cART. Multivariate models demonstrated improved survival associated with increased recent CD4, reduced recent viral load, younger patients, absence of HBVsAg-positive ever, year of HIV diagnosis and incidence of ADI. Parametric models showed a fairly constant mortality risk by year of cART up to 15 years of treatment. Conclusion: Observed mortality remained fairly constant by duration of cART and was modelled accurately by accepted prognostic factors. These rates did not vary much by duration of treatment. Changes in mortality with age were similar to those in the Australian general population.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine
    Sabin, CA
    Fisher, M
    Churchill, D
    Pozniak, A
    Hay, P
    Easterbrook, P
    Williams, I
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (05) : 462 - 465
  • [2] High rate of long-term clinical events after antiretroviral therapy resumption in HIV-positive patients exposed to antiretroviral therapy interruption
    Richart, Valeria
    Fernandez, Irene
    de Lazzari, Elisa
    Berrocal, Leire
    Feher, Csaba
    Plana, Montserrat
    Leal, Lorna
    Garcia, Felipe
    [J]. AIDS, 2021, 35 (15) : 2463 - 2468
  • [3] Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era
    King, JT
    Justice, AC
    Roberts, MS
    Chang, CCH
    [J]. MEDICAL DECISION MAKING, 2003, 23 (01) : 9 - 20
  • [4] Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro
    Jevtovic, D. O.
    Salemovic, D.
    Ranin, J.
    Pesic, I.
    Zerjav, S.
    Djurkovic-Djakovic, O.
    [J]. HIV MEDICINE, 2007, 8 (02) : 75 - 79
  • [5] Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy
    Guerrero, MLF
    Rivas, P
    Molina, M
    Garcia, R
    De Górgolas, M
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (03) : 390 - 394
  • [6] Changes in HIV reservoirs during long-term antiretroviral therapy
    Hong, Feiyu F.
    Mellors, John W.
    [J]. CURRENT OPINION IN HIV AND AIDS, 2015, 10 (01) : 43 - 48
  • [7] Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients
    Dupont, C
    Vasseur, E
    Beauchet, A
    Aegerter, P
    Berthé, H
    de Truchis, P
    Zucman, D
    Rouveix, E
    Saiag, P
    [J]. AIDS, 2000, 14 (08) : 987 - 993
  • [8] Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy
    Bozzette, Samuel A.
    Ake, Christopher E.
    Tam, Henry K.
    Phippard, Alba
    Cohen, David
    Scharstein, Daniel O.
    Louis, Thomas A.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (03) : 338 - 341
  • [9] Long-term Outcomes of Patients With HIV and Pneumocystis jirovecii Pneumonia in the Antiretroviral Therapy Era
    Epling, Brian P.
    Manion, Maura
    Sirajuddin, Arlene
    Laidlaw, Elizabeth
    Galindo, Frances
    Anderson, Megan
    Roby, Gregg
    Rocco, Joseph M.
    Lisco, Andrea
    Sheikh, Virginia
    Kovacs, Joseph A.
    Sereti, Irini
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (08):
  • [10] Prospective follow-up of HIV positive patients with and without access to antiretroviral therapy: survival and complications
    Wolff, M
    Diomedi, A
    Morales, O
    Bidart, T
    Dabanch, J
    Bustamante, C
    Northland, R
    [J]. REVISTA MEDICA DE CHILE, 2001, 129 (08) : 886 - 894